What is Jardiance or empagliflozin approved for in India
Jardiance or empagliflozin has been approved for the treatment of adults with chronic kidney disease in India.
- Jardiance or empagliflozin is approved for the treatment of adults with chronic kidney disease in India.
- Chronic kidney disease (CKD) is a condition where the kidneys are damaged and can't filter blood properly, leading to a build-up of waste products in the body.
- Jardiance belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors.
- It works by blocking the action of a protein called SGLT2 in the kidneys, which reduces the reabsorption of glucose and increases its excretion in the urine.
- This mechanism helps lower blood sugar levels in people with diabetes, as well as enabling better kidney function by reducing glucose reabsorption in the kidneys.
- Studies have shown that Jardiance can reduce the risk of kidney failure, cardiovascular events, and mortality in people with CKD and type 2 diabetes.
- It is important to note that Jardiance should be used under medical supervision and as part of a comprehensive treatment plan for chronic kidney disease.
Answered
a year ago